datopotomab deruxtecan

WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer
Endpoints
Fri, 01/29/21 - 10:03 am
AstraZeneca
WCLC
antibody-drug conjugate
datopotomab deruxtecan